ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$64.95 USD
-0.48 (-0.73%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $64.94 -0.01 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
Cash flow Statements
Fiscal Year End for ANI Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 18.78 | -47.90 | -42.60 | -22.55 | 6.09 |
Depreciation/Amortization & Depletion | 59.79 | 59.65 | 47.25 | 44.64 | 44.61 |
Net Change from Assets/Liabilities | 24.86 | -51.30 | -0.08 | -12.63 | -14.58 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 15.53 | 8.34 | -1.24 | 5.81 | 9.51 |
Net Cash From Operating Activities | 118.96 | -31.20 | 3.32 | 15.27 | 45.63 |
Property & Equipment | -8.87 | -8.13 | 0.09 | -6.14 | -6.64 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -0.03 | -84.49 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | -9.64 | -7.58 | -21.08 | -62.19 | -20.91 |
Net Cash from Investing Activities | -18.51 | -15.74 | -105.48 | -68.32 | -27.55 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 84.56 | -0.50 | 101.18 | -0.91 | 4.71 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -10.86 | 6.97 | -2.71 |
Increase (Decrease) Short-Term Debt | -3.00 | -3.00 | 123.85 | -7.50 | -0.75 |
Payment of Dividends & Other Distributions | -1.63 | -1.63 | -0.19 | 0.00 | 0.00 |
Other Financing Activities | -12.50 | 0.00 | -19.38 | 0.00 | 0.00 |
Net Cash from Financing Activities | 67.44 | -5.13 | 194.60 | -1.44 | 1.25 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 167.89 | -52.07 | 92.43 | -54.49 | 19.33 |
Cash at Beginning of Period | 53.23 | 105.30 | 12.87 | 67.36 | 48.03 |
Cash at End of Period | 221.12 | 53.23 | 105.30 | 12.87 | 67.36 |
Diluted Net EPS | 0.85 | -3.05 | -3.40 | -1.88 | 0.50 |
Fiscal Year End for ANI Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 18.78 | 17.62 | 7.68 | 1.44 |
Depreciation/Amortization & Depletion | NA | 59.79 | 44.60 | 29.39 | 14.70 |
Net Change from Assets/Liabilities | NA | 24.86 | -2.94 | -8.50 | -1.77 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 15.53 | 14.94 | 13.48 | 7.06 |
Net Cash From Operating Activities | NA | 118.96 | 74.22 | 42.05 | 21.42 |
Property & Equipment | NA | -8.87 | -6.59 | -4.85 | -2.35 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | -9.64 | -7.14 | -4.33 | 0.00 |
Net Cash from Investing Activities | NA | -18.51 | -13.73 | -9.18 | -2.35 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 84.56 | 82.83 | 77.92 | -3.39 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | -3.00 | -2.25 | -1.50 | -0.75 |
Payment of Dividends & Other Distributions | NA | -1.63 | -1.22 | -0.81 | -0.41 |
Other Financing Activities | NA | -12.50 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 67.44 | 79.36 | 75.60 | -4.55 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 167.89 | 139.84 | 108.47 | 14.52 |
Cash at Beginning of Period | NA | 53.23 | 53.23 | 53.23 | 53.23 |
Cash at End of Period | NA | 221.12 | 193.08 | 161.71 | 67.76 |
Diluted Net EPS | NA | 0.05 | 0.45 | 0.29 | 0.06 |